Photoreceptor Structure in A Phase 2 Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Rates of Change in Cone Spacing and Density
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2016
At a glance
- Drugs NT 501 (Primary)
- Indications Retinitis pigmentosa; Usher syndromes
- Focus Therapeutic Use
- Sponsors GNT Pharma
- 26 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 29 Mar 2016 Planned End Date changed from 1 Jun 2019 to 1 Aug 2019, according to ClinicalTrials.gov record.
- 29 Mar 2016 Planned primary completion date changed from 1 Jun 2019 to 1 Aug 2019, according to ClinicalTrials.gov record.